TAK-243 is also undergoing Phase 1 clinical trials in patients with refractory acute myeloid leukemia (AML) to block UBA1, UBA6, and NAE targeted proteins involved in tumor cell division (ClinicalTrials.gov Identifier: NCT03816319). This evidence concerns the gene UBA1 and acute myeloid leukemia.